Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Subscribe To Our Newsletter & Stay Updated